27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Alaunos Therapeutics Inc (NASDAQ:TCRT) announced early clinical findings from its ongoing TCR-T Library Phase 1/2 trial.
- "We are excited to announce early findings from our TCR-T Library trial. This is the first time that an objective clinical response has been observed in a solid tumor cancer in connection with non-viral TCR-T cell therapy," said Kevin S. Boyle, Sr., CEO of Alaunos.
- The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation study enrolling patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers with a matching human leukocyte antigen (HLA) and hotspot mutation pairing in Alaunos' TCR library.
- The first patient dosed was diagnosed with non-small cell lung cancer with a KRAS G12D mutation. The patient received TCR-T cells and had a confirmed objective partial response.
- The company has dosed a second patient in the study, diagnosed with colon cancer, who has been treated at the second dose level and has cleared the 28-day safety window.
- Price Action: TCRT shares are up 6.20% at $3.08 on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!